Crescent Biopharma
CBIO
58 hedge funds and large institutions have $72.5M invested in Crescent Biopharma in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 22 reducing their positions, and 29 closing their positions.
14% more call options, than puts
Call options by funds: $1.06M | Put options by funds: $931K
10.56% less ownership
Funds ownership: 71.21% → 60.65% (-11%)
26% less funds holding
Funds holding: 78 → 58 (-20)
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
69% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 29
73% less capital inflows, than outflows
Capital inflows: $5.53M | Capital outflows: $20.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.62M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$780K |
| 3 |
E
Ergoteles
New York
|
+$409K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$346K |
| 5 |
Renaissance Technologies
New York
|
+$334K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.93M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
-$3.19M |
| 3 |
Two Sigma Investments
New York
|
-$1.63M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.3M |
| 5 |
SCM
Sio Capital Management
New York
|
-$1.07M |
CBIO Hedge Fund Activity: Q2 2021 in Review
58 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2021, worth a combined $72.5M — down 34% from $110M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of CBIO and 9 opened new positions — a net loss of 20 holders — while 22 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, adding an estimated $1.62M. The largest seller was BlackRock, cutting an estimated $4.93M.
- 58 institutional investors held Crescent Biopharma (CBIO) as of Q2 2021, down from 78 in Q1 2021.
- Funds reported $72.5M of Crescent Biopharma stock for Q2 2021, down 34% quarter-over-quarter.
- 9 funds opened new Crescent Biopharma positions in Q2 2021 and 29 closed out, a net change of -20 holders.
- The largest Crescent Biopharma buyer in Q2 2021 was Millennium Management, an estimated $1.62M added.
- The largest Crescent Biopharma seller in Q2 2021 was BlackRock, an estimated $4.93M sold.
Based on aggregated 13F filings for Q2 2021.